FDA Grants Orphan Designation to PTX-100 for TCL Indications
Clinical-stage oncology company Prescient Therapeutics (ASX:PTX) has announced that the US FDA has granted Orphan Drug Designation for PTX-100 for the
FDA Grants Orphan Designation to PTX-100 for TCL Indications
